MEMO RE Covid-19 Federal Govt Regulatory Failures, Crimes and Attempts to Avoid Liability.docx


Executive Summaries of Exhibits/

    2023.01.08-latypova-memo-dod-barda-role.pdf
    cGMP Noncompliance.docx
    cGMP Noncompliance.pdf
    DOD BARDA OTA Contracts.docx
    DOD BARDA OTA Contracts.pdf
    Legal History of American Domestic Bioterrorism Program.docx
    Legal History of American Domestic Bioterrorism Program.pdf


Supporting Documentation for Exhibits/

    cGMP noncompliance/
        Brandon Johnson supplement Coker v Austin.pdf
        M1 20 Nov 2020 FDA Query Res19.pdf

        Analysis of BNT162b2 Manufacture/
            22OC29_EMA-Analysis-of-BNT162b-Manufacture (1).pdf
            CCCA Presentation.pptx
            alexandra-latypova-expert-report-docx.pdf

        Batch variability analysis/
            Covid_vs_Flu_vax_v1.pdf
            Failure to Scale - Test the vials.pdf
            Hot Lot Update_Jul15 2022.pdf
            alexandra-latypova-expert-report-docx.pdf

            Technical appendix/
                LtL Variability Analysis.xlsx
                Mod_Lot_041L20A-allAE-allGeo-datevax.xlsx

                C19V Source data/
                    All C19 Manuf_LotN_US_AllAE.txt
                    All C19 Manuf_LotN_US_SAEonly.txt
                    All C19 manuf Foreign_All AE.txt
                    All C19 manuf Foreign_Deaths.txt
                    All C19 manuf Foreign_SAE.txt

                Flu source data/
                    FLU_INJECT_AllManuf_US.txt
                    FLU_INJECT_AllManuf_US_Deathonly.txt
                    FLU_INJECT_AllManuf_US_SAEOnly.txt

        EMA Leaked emails/
            EMA LEAKS/
                MLT rolling report on COVID-19 discussions.docx
                Nov 22.PNG
                Nov 23.png
                Nov11.PNG
                Nov12-II.PNG
                Nov12.PNG
                Nov16.PNG
                Nov19.PNG
                Nov20.PNG
                Nov23-II.PNG
                Nov23.PNG
                Nov24.PNG
                Nov25-II.PNG
                Nov25.PNG
                before Nov21.PNG

        Evidence of harm from countermeasures/
            Benzi+Cipelli+et+al.+proof+1.12.pdf
            EvidentiaryDocument_COVID19NationalLevelHarm_01122022.pdf
            M Palmer organ damage causality.pdf

        FDA audit forms 483/
            Rentschler Biopharma, Laupheim, Germany 2.15.22_483.pdf
            applied-KM-Catalent Indiana LLC_FEI 3005949964_483-09_01_2022_Redacted.pdf

        HRees Expert Report Supply Chain cGMP/
            Hedley Expert report_17122021.pdf

        Independent testing of vax vials/
            2021-Nov  Analyse 2_Neu.pdf
            26 groups imaging finding JVTPR.pdf
            Dr Schmidt-Kruger - Summary.docx
            Report on contaminants in Cov-Injections.pdf
            V1 working group vax vial analysis.pdf
            alignment biontech.xlsx

        Other Transaction Authority/
            2020.06.29 KEI Brief on OTA KEI-Briefing-OTA-29june2020.pdf

        Regulatory Review Documents/
            20201126_BNT162b2_EMAmeeting14.pptx
            COVID-19 mRNA Vaccine BioNTe24.docx

    Role of DOD and BARDA/
        2020.06.29 KEI Brief on OTA KEI-Briefing-OTA-29june2020.pdf
        FDA Briefing on Development of C-19 Vaccines.pdf
        Medical CBRN Defense Consortium_Pfizer and Novavax.pdf
        NIH-Moderna-Confidential-Agreements.pdf
        VRBPAC-10.22.20-Meeting-Presentation-COVID19-Vaccine-Development-NIH-Role.pdf
        VRBPAC-10.22.20-Meeting-Presentation-COVID19-Vaccine-Development-Portfolio.pdf
        signal-2022-11-16-07-58-29-843.mp4

        DOD-BARDA contracts for countermeasures/
            BARDA-ModernaTX-Contract-75A50120C00034-16Apr2020.pdf
            BARDA-Protein-Sciences-Corp-Contract-HHSO100201600005I-14Feb2020.pdf
            DOD-ATI-Contract-MCDC-Consortium-W15QKN1691002-P00085-8April2016.pdf
            DOD-ATI-Janssen-Contract-W15QKN1691002-P00081-Mod00001-21Sept2020.pdf
            DOD-ATI-Novavax-Contract-W15QKN1691002-25June2020.pdf
            DOD-ATI-Novavax-TDL-SOW-W15QKN1691002-6July2020-21Dec2020.pdf
            DOD-ATI-Novavax-Technical-Direction-Letter-W15QKN1691002-6July2020-HHSRR.pdf
            DOD-ATI-Pfizer-Technical-Direction-Letter-OTA-W15QKN-16-9-1002-21July2020.pdf
            DOD-GlaxoSmithKline-Contract-W15QKN20C0048-P00001-30July2020.pdf
            DOD-GlaxoSmithKline-Contract-W15QKN20C0048-P00002-16Sept2020.pdf
            DOD-Moderna-Contract-W911QY20C0100-9Aug2020-HHSFOIAReadingRoom.pdf
            DOD-Moderna-Contract-W911QY20C0100-P00007-15June2021.pdf
            DOD-Novavax-Contract-W911QY20C0077-P00001-4June2020.pdf
            DOD-Ology-Bioservices-Contract-W911QY2090003-21Feb2020.pdf
            DOD-Ology-OTA-W911QY2090003-21Feb2020.pdf
            DOD-Ology-OTA-W911QY2090003-Appendix A-4-20Mar2020.pdf
            DVA-Pfizer-Contract-V797D40269-P00376-1June2021.pdf
            DoD-Icon-OTA-Contract-W911QY2090007-27April2020.pdf
            DoD-Inovio-Contract-18June2020.pdf
            DoD-Inovio-OTA-22June2020.pdf
            DoD-Novavax-Statement-of-Work-W15QKN1691002.pdf
            DoD-Ology-Bioservices-Contract-W911QY20C0101-17Aug2020.pdf
            DoD-Pfizer-Contract-W15QKN21C0012-22Dec2020.pdf
            HHS-BARDA-Emergent-Contract-HHSO100201200004I-15June2012.pdf
            HHS-BARDA-Emergent-Contract-HHSO100201200004I-75A50120F33007-24May2020.pdf
            HHS-BARDA-Emergent-Contract-HHSO100201200004I-75A50120F33007-P00001-24Aug2020.pdf
            HHS-BARDA-Emergent-Contract-HHSO100201200004I-75A50120F33007-P00002-13May2020.pdf
            HHS-BARDA-Emergent-Contract-HHSO100201200004I-75A50120F33007-P00003-7Oct2020.pdf
            HHS-BARDA-Emergent-SupplyOrder-Contract-HHSO100201200004I-24May2020.pdf
            HHS-BARDA-J&J-OTA-HHSO100201700018C-Amendment8-27March2020-FOIA.pdf
            HHS-BARDA-Moderna-Contract-75A50120C00034-16April2020-Version8Feb2021.pdf
            HHS-BARDA-Moderna-Contract-75A50120C00034-P00003-25July2020.pdf
            HHS-BARDA-TexasAM-Contract-HHSO100201200002I-75A50120F33002-23July2020.pdf
            HHS-BARDA-TexasAM-Contract-HHSO100201200002I-75A50120F33002-P00001-27Aug2020.pdf
            HHS-BARDA-TexasAM-Contract-HHSO100201200002I-75A50120F33002-P0002-9Oct2020.pdf
            HHS-BARDA-Vaxess-Technologies-Contract-75A50120C00160-6Aug2020.pdf
            HHS-Protein-Sciences-Sanofi-Contract-HHSO100201600005I-16Aug2016.pdf

            NIAID-Moderna/
                NIH-Moderna-Confidential-Agreements.pdf

Other affidavits/
    COVID Vaccine Death Excess and cGMP Fraud Summary of Evidence 10 19 2022.pdf

    Affidavit on 33 Pfizer batches/
        ALatypova Affidavit_GMP violations Pfizer batches_12-2022.pdf

        Attachments/
            20201126_BNT162b2_EMAmeeting14.pptx
            33-Pfizer batch-details tables.xlsx
            COVID-19 mRNA Vaccine BioNTe24.docx
            Latypova-Resume_102022.pdf
            M1 20 Nov 2020 FDA Query Res19.pdf

    Affidavits on non-clinical Pfizer and Moderna/
        ALatypova Moderna Affidavit 2 Dec 21 2022.docx
        Pfizer nonclinical review for DC$E website.pdf

    BARDA affidavit/
        BARDA subverts pharmacy regulations.docx

        Attachments - BARDA affidavit/
            signal-2022-11-16-07-58-29-843.mp4

    BARDA FOIA from CHD/
        2023-00322-FOIA-OS - responsive documents.pdf
        Final Response Letter - Full Release .pdf

    Pfizer batch variability witness statement/
        20201126_BNT162b2_EMAmeeting14.pdf
        Nov23.PNG
        Rapporteurs-Rolling-Review-Report-Quality-COVID-19-mRNA-Vaccine-BioNTec.doc
        Witness statement_VaxVariability_AlexandraLatypova.docx